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Abstract Iron oxide nanoparticles (IONPs) occupy a 
privileged position among magnetic nanomaterials with 
potential applications in medicine and biology. They 
have been widely used in preclinical experiments for 
imaging contrast enhancement, magnetic resonance, 
immunoassays, cell tracking, tissue repair, magnetic 
hyperthermia and drug delivery. Despite these promising 
results, their successful translation into a clinical setting is 
strongly dependent upon their physicochemical 
properties, toxicity and functionalization possibilities. 
Currently, IONPs-based medical applications are limited 
to the use of non-functionalized IONPs smaller than 100 
nm, with overall narrow particle size distribution, so that 
the particles have uniform physical and chemical 
properties. However, the main entry of IONPs into the 
scene of medical application will surely arise from their 
functionalization possibilities that will provide them with 
the capacity to target specific cells within the body, and 
hence to play a role in the development of specific 
therapies. In this review, we offer an overview of their 
basic physicochemical design parameters, giving an 
account of the progress made in their functionalization 
and current clinical applications. We place special 
emphasis on past and present clinical trials. 
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Over the last decade, nanotechnology has become more 
relevant in many industrial sectors, including medicine. In 
general, the future projection and promotion of iron oxide 
nanoparticles (IONPs) as a point of reference among other 
magnetic nanomaterials for clinical applications relies 
chiefly on their biocompatibility in moderate doses, their 
relatively well-known iron metabolic pathways and their 
ability to be produced in a wide range of sizes and shapes 
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with biofunctionalization potential. Additionally, the 
added advantage of magnetic actuation makes IONPs 
stand out from many other nanotechnology-based 
therapeutic and diagnostic approaches. In any case, IONPs 
have already passed through the preclinical stage to 
become a reality in clinical practice. In particular, they 
improve imaging-based diagnostics of immunological 
diseases, cardiovascular and cerebrovascular pathologies 
and cancer. They show great promise to serve as a cell 
tracking system in cell-based therapies, and to generate 
local temperature increases in the magnetic thermotherapy 
of solid tumours. 
 
The purpose of this work is to review the basic parameters 
involved in the design of IONPs and their functionalization 
possibilities which, in the next few years, will bring into 
being a completely new generation of IONPs with selective 
targeting properties. Functionalized and 
multifunctionalized IONPs will become nanocarriers that 
will improve the selectivity of specific cells and, therefore, 
allow for the development of specific therapies. We 
describe their biochemical features, their cell 
internalization and in vivo administration, as well as the 
reduced toxicology effects that have contributed to their 
successful use in current clinical applications. Additionally, 
we discuss most of the past and present clinical trials 
involving IONPs, placing special emphasis on their 
interactions with different compartments of the immune 
system. Finally, we highlight the potential advances in 
functionalization and magnetic hyperthermia as two fields 
that will surely push forward the clinical use of IONPs. 
 




This is arguably the most important parameter upon 
which any IONPs system must be designed. First, it 
profoundly affects the dynamics of the magnetic 
moments in magnetic NPs―also regarded as the 
magnetic relaxation processes―that also depend on other 
parameters, such as temperature or externally applied 
magnetic fields. Second, particle size is of paramount 
importance in the detection, internalization and eventual 
fate of IONPs inside mammalians. 
 
Two of the most relevant magnetic scale lengths that 
characterize magnetic NP systems are the 
superparamagnetic radius (RSPM) and the single domain 
radius (RSD). RSPM refers to the maximum particle size up to 
which a superparamagnetic regime is observed. RSD 
indicates the value below which the formation of magnetic 
domains―regions grouping magnetic moments with the 
same orientation―is no longer energetically favourable 
and indicates that the most stable magnetic configuration 
for the particle is the single domain state [1]. Both RSD and 
RSPM can be worked out from the anisotropy constant (K), 
the dimensionless hardness parameter (κ) and the 
exchange stiffness constant (A) [2] of the material of 
interest. Table 1 summarizes these parameters for 
maghaemite and magnetite, the most commonly used iron 
oxides in biomedicine, and gives a glimpse of the range of 
magnetic behaviours of IONPs with varying particle size. 
 
IONPs may be produced by a number of methods that 
allow for precise control over their size, shape and surface 
chemistry [3][4][5][6]. These parameters, along with others, 
can be used to classify IONPs for different purposes [7]. 
With reference to particle size, the researchers working on 
IONPs in medicine and biology―especially in the MRI 
community―use an informal classification divided into 
distinct ranges as follows: below 10 nm, very small 
superparamagnetic iron oxide NPs (VSPIONs); between 
10 and 50 nm, ultrasmall superparamagnetic iron oxide 
NPs (USPIONs); and between 50 and 180 nm, 
superparamagnetic iron oxide NPs (SPIONs). 
 
Although this classification might be useful only for the 
purpose of gathering some size ranges showing similar 
circulation and relaxational properties for specific 
applications, IONPs are persistently referred to in the 
literature as SPIONs, regardless of their true magnetic 
properties. This misuse of the term SPION is both 
inaccurate and confusing, as the lower-end value of the 
SPIONs’ size range lies at the theoretical transition 
between superparamagnetic and single domain states for 
iron oxides (Table 1). Thus, most of the particle sizes 
encompassed within this range would in fact be single 
domain, not superparamagnetic. Interparticle interactions 
and surface effects further complicate this picture by 
shifting RSPM away from its theoretical value. Therefore, we 
recommend avoiding, where possible, the SPION-based 
nomenclature and using a more general one describing the 
actual behaviour of the IONPs experimentally 
characterized by magnetic measurements, either: (i) based 
on size effects (superparamagnetic, single domain and 
multidomain) or (ii) on the coupling between magnetic 
moments (ferro-, ferri-, or antiferromagnetic, as applicable). 
Another source of confusion is the conflation of the 
numerical size values measured by different techniques, 
more specifically the “physical” size―typically obtained 
through electron microscopy, X-ray diffractometry, or 
similar means―and the hydrodynamic size―measured by 
dynamic light scattering or acoustic spectroscopy, and a 
value that, besides the physical particle size, also takes into 
account the thickness of any coating agent and the 
solvation molecules from the solvent. A final word of 
caution in this regard is that many IONPs are prepared by 
forming aggregates of variable size instead of a dispersion 
of single NPs; the size of the aggregates―often referred to 
as multi-cores―and that of the single particles are 
sometimes carelessly conflated. 






 (J/m3) (J/m)  (A/m) (nm) (nm)  (nm)
Maghemite 4.6×103 ~10-11 3.8×105 0.16 7.4 42.5 17.5 
Magnetite 1.35×104 1.33×10-11 4.8×105 0.21 6.8 52.7 12.2 
Iron 4.8×104 1.49×10-11 1.71×106 0.11 2.0 8.3 8.0 





Figure 1. Membrane deformation for (a) shallow wrapping and (b) deep wrapping of a cubic-shaped nanoparticle. The network of 
edges and triangles describes the membrane shape and has been used for the numerical calculation of the curvature energy. [Adapted 
with permission from S. Dasgupta, et al., Nano Letters 14(2) (2014) 687-693. Copyright 2014 American Chemical Society]. (c) Values of 
diffusion length (ldiff) of nanoparticles as a function of particle size (R) at fixed values of aspect ratio (a) [Reprinted with permission from 
X. Li, Journal of Applied Physics, vol. 111 (2012) 024702. Copyright 2012, AIP Publishing LLC]. (d) Normalized absorption rate of 
cylindrical particles with different diameters and aspect ratios [Permission pending]. 
 
From a biological point of view, IONPs can travel 
anywhere through the circulatory system of the human 
body, since the smallest capillaries are 4-6 μm wide [8]. 
IONPs under 100 nm are considered to be suitable for any 
application requiring tissue penetration, but those around 
5 nm are more effective for tumour penetration [9]. 
Nonetheless, at the cellular level, NP size also influences 
the binding affinity of molecules, the uptake of additional 
particles into the cell, and the actual location within the 
cell. For a given NP shape, there is an optimal size for NP 
diffusion through the potential barrier characterizing the 
particle–cell interaction, as found by theoretical models 
[10][11]. Numerical calculations of these models indicate 
that the optimal NP size for a reasonably quick 
endocytosis is somewhere around 25 to 35 nm. 
Regardless of the particular considerations in each of the 
proposed models, the aforementioned optimum size 
range is given by the interplay between the kinetics and 
thermodynamics of the diffusion–absorption process of 
NPs relative to the thermal energy involved. Of particular 
note is that within the framework of the model proposed 
by Shi et al., the optimum particle sizes obtained do not 
depend on the absorption coefficient, the viscosity of the 




Consider a magnetic particle as composed of many 
positive and negative poles; these will cancel each other, 
but there will still be free poles at the surface of the 
particle. These free poles create a magnetic field―the 
demagnetizing field (Hd)―that depends on the particle 
shape and is opposed to the direction of the external field 
(Hext). It follows that the effective magnetic field (Heff) 
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acting on a particle will be different from Hext:Heff = Hext - 
Hd, where Hd = N·M, with M the magnetization of the 
particle and N the so-called demagnetizing factor (N). In 
the case of a spherical shape, N = 1 due to the even 
distribution of free poles over the particle’s surface. Other 
morphologies different from a perfect sphere―the usual 
case in many real systems―may be approximated to 
distorted ellipsoids. In this way, the anisotropy energy 
associated with the shape of an ellipsoidal particle with 
its major axis lying along the z direction equals [12]: Eshape
= [μ0MS2(Nx-Nz)/2]-1, where MS is the saturation 
magnetization and μ0 is the permeability of the free space.  
 
Besides its contribution to the total anisotropy energy of 
magnetic particles, the role of the particle shape in the 
magnetic properties of NPs is linked to the stability of the 
single domain configuration. For example, disc-like NPs 
with relatively higher aspect ratios may show a closed 
spiral arrangement of their magnetic moments [13], called 
a vortex state, whereas particles with the same shape but 
lower aspect ratios show the typical parallel arrangement 
of moments commonly seen in uniformly magnetized 
single domain NPs [14]. 
 
On the biological side, the shape of an NP determines the 
extent to which the NP will interact with membrane 
receptors and hence the degree of internalization. Shi et
al. modelled the particle–cell interaction by considering 
the diffusion and absorption of rod-like (cylindrical) and 
spherical NPs through a partially absorbing spherical cell 
[15]. For a fixed set of physical parameters of the 
particles, cell and medium, numerical results show that 
for each NP size there is a specific aspect ratio value for 
which the absorption rate is maximum (red region in 
Figure 2A), demonstrating the joint relevance of the size 
and shape of NPs to their internalization. Strange as it 
may seem, the outcomes of this work also suggest that 
the optimum particle size and shape for endocytosis do 
not depend noticeably on either the particular NP’s 
absorption mechanism or the viscosity of the medium. 
Subsequent models based on similar grounds coincide in 
more general aspects. Noticeably, in particles with 
increasing aspect ratios, endocytosis becomes 
energetically favourable with decreasing particle sizes 
(Figure 2B). Particle orientation adds to the intricate 
influence of particle shape. Recent theoretical calculations 
based on membrane mechanics show how possible 
particle wrapping states―designated as shallow (Figure 
2C) and deep (Figure 2D)―evolve, depending on the 
particle aspect ratio and edge curvature [16]. The 
proposed model predicts that particles with a high aspect 
ratio and round tips enter the cell membrane with their 
long edge parallel to the membrane, whereas those with 
low aspect ratio and sharp edges proceed tip-first. 
Despite its intrinsic limitations, this model provides the 
basis for making predictions of particle toxicity 
considering particles’ shape and wrapping degree. Other 
studies on the interaction between other types of 
nanostructures, like nanosheets or nanotubes, and cell 
membranes have been reviewed elsewhere [17]. 
Although some of the results reported for these 
nanostructures sharply differ from those for NPs, many 
others are consonant; for instance, some aspects relating 
to the uptake mechanism of nanotubes and elongated 
NPs with variable edge curvature [17][18]. Finally, the 
circulation and the eventual in vivo fate of IONPs inside 





Figure 2. Schematic representation of the theoretical magnetic regimes (superparamagnetic, single domain, multidomain) expected for 
both magnetite and maghaemite, along with some relevant applications as a function of the particle size. (*) Magnetofection is a 
trademark of Christian Bergemann and Dr Christian Plank. (**) Refers to uncoated, single nanoparticles. The size ranges represented are 
approximate and comprise the most common cases. 
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2.3 Surface charge density 
An additional degree of complexity linked to the biological 
activity of NPs is constituted by their effective superficial 
charge, which determines the type of active or passive 
functionalization through specific molecules and the 
relevant particle–cell interaction mechanisms, which is 
revisited in the following sections. In this regard, the 
magnetic properties of NPs would remain virtually 
unaffected by their surface charge, even though the coating 
used to tune the surface charge or the affinity for a 
particular target may introduce sizeable modifications, as 
discussed later. As a first approximation, bare IONPs 
possess a surface charge strongly influenced by the 
environment, involving the pH and the ionic strength of 
the medium. The point of zero charge (PZC), that is, the 
pH values for which the surface charge density is zero, for 
bare IONPs may span several pH units depending on the 
type and concentration of charged species in the medium. 
For magnetite, it has been reported to range between 3.9 
and 9.9 [20], and for maghaemite the reported range is 
around 3.3-7.5 depending on the reaction conditions [21]. 
Besides the PZC, another surface charge parameter of 
interest is the zeta-potential (ζ) [22][23], whose sign and 
value give an idea of the colloidal stability of NP 
suspensions rather than focusing exclusively on the 
isolated particles. It is commonly accepted that a stable 
colloidal suspension of IONPs has approximately ζ < -30 
mV or ζ > +30 mV. Nevertheless, bare IONPs as such are of 
very limited interest for biomedical applications, due to 
their non-specificity, tendency to aggregation and short 
circulation times, as well as their toxicity, since they may 
induce vacuole formation and other cell damage leading to 
cell death [24]. In order to manipulate the surface charge, 
improve their biocompatibility and/or add a specific 
functionality (see section 2), IONPs can be coated with a 
large number of molecules by virtue of their relatively 
wide PZC range discussed above. 
 
The surface charge of both bare and coated IONPs 
influences the binding to cell membranes as the limiting 
step in their internalization process [25], irrespective of the 
shape. It is rather the sign of the charge that determines the 
internalization mechanism [26]. Membrane interaction can 
occur regardless of the charge of NPs, but it is well known 
that positively- or negatively-charged IONPs are 
internalized more rapidly than neutral ones. For instance, 
in vitro studies with L929 fibroblasts and Saos-2 osteoblasts 
reveal how the uptake of negatively-charged SPIONs 
(coated with dimercaptosuccinic acid, DMSA) and 
positively-charged SPIONs (coated with (3-aminopropyl) 
triethoxysilane, APS) is far superior to that of neutral 
SPIONs (coated with dextran) [27]. This charge-mediated 
internalization enhancement may lead to cell damage for 
concentrations of DMSA and APS-coated SPIONs above 
0.10 mg/mL in L929 fibroblasts and 0.20 mg/mL in Saos-2 
osteoblasts. Mahmoudi et al. have found that positively-
charged SPIONs promote amyloid-β protein fibrillation at 
significantly lower particle concentrations than neutral or 
negatively-charged SPIONs [28].  
 
A good example of how surface charge may affect the fate 
of similar IONPs formulations inside mammalians arises 
from the comparison of ferumoxides (ζ = –32 mV), 
ferumoxytol (ζ = –49 mV) and ferumoxtran (ζ = –2 to 0 
mV). The latter has a thicker dextran layer [29] to avoid 
opsonization (protein adsorption) typically seen in very 
small particles and increase its circulation time, but in 
exchange is internalized to a lesser extent due to its almost 
neutral ζ. On the other hand, ferumoxides and ferumoxytol 
do not adsorb proteins and do not readily become 
opsonized, but are removed from circulation by the 
reticuloendothelial (RES) system due to their negative ζ. 
 
3. Functionalization of IONPs 
 
Functionalization of IONPs with biomolecules is a subject 
of great interest for two aspects related to their clinical 
applications. First, IONPs can be used as nanocarriers for 
drug delivery to tackle drug resistance of cancer cells and 
to increase local drug concentrations. Second, IONPs can 
be functionalized with specific targeting agents in order 
to improve the selectivity of specific cells, such as cancer 
cells, and therefore improve the selectivity, reduce side 
effects and increase local concentrations of drugs and/or 
IONPs in the targeted tissue. All these strategies are 
involved in the development of new generations of 
functionalized and multifunctionalized NPs for 
biomedical applications that introduce selective targeting 
properties to such nanocarriers. 
 
The effect of targeting is strongly related to the 
enhancement of cellular uptake. Indeed, targeting 
strategies involve the recognition and binding to 
membrane receptors overexpressed on targeted cells, 
which changes the cellular uptake pathway and its 
efficiency. Several functionalization and targeting 
strategies have been developed in parallel with the latest 
advances in the discovery of new biomarkers specific to 
the different types of cells considered (e.g., cancer cells, 
cancer stem cells, etc.). 
 
Currently, no clinical trials are in progress concerning the 
use of functionalized IONPs in humans. However, almost all 
the scientific publications in the field mention the potential 
biomedical and clinical applications of functionalized IONPs 
considering the promising in vitro and in vivo results. Among 
the wide diversity of molecules that have been used for the 
functionalization of IONPs described hereafter, most are 
already accepted by the different drug regulation 
administrations or are now in late clinical trial phases. 
Similarly, the IONP-based formulations ferumoxytol and 
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GastroMARK are also approved. Therefore, the combination 
of both IONPs and specific functionalities shows great 
potential in the near future for the generation of novel 
nanoformulations for clinical use. 
 
Here, we present an overview of the different molecules 
that are currently used for the functionalization of IONPs, 
highlighting some relevant examples and their potential 
in clinics (Table 2 and Figure 3). 
 
3.1 Cell-penetrating peptides (CPPs) 
 
Cell-penetrating peptides (CPPs), also known as protein 
transduction domains (PTDs) are up to 30-amino acid 
amphiphilic peptides that can be internalized by cells 
using mechanisms that require no energy and that can be 
receptor-mediated or not. Among the large variety of 
CPPs sequences, the presence of positively-charged 
amino acids and the amphiphilic character are the two 
common characteristics [30]. First used for intracellular 
delivery of macromolecules [31], CPPs are very 
interesting as drug and NPs intracellular delivery 
carriers. IONPs functionalized with different amounts of 
Tat peptide showed an exponential increase of cell uptake 
by increasing the number of CPPs grafted onto IONPs, 
concluding in a multivalent effect on the internalization  
 
[32]. The important parameters for the entrance of CPPs 
are positive charge and amphiphilic character. Martin et 
al. [33] and Cavalli et al. [34] studied the use of guanidine-
based dendritic structures and synthetic peptides 
mimicking CPPs’ properties for IONP functionalization. 
Both studies, with different cell lines, had comparable 
results to the ones observed with CPPs. The interest in 
using synthetic structures is due to their stability toward 
protease degradation. These examples show that the 
conjugation of IONPs with CPPs and analogue peptides 
with similar physical properties can be used to improve 
the cellular uptake of IONPs.  
 
Additionally, newly identified tumour-homing CPPs 
have been discovered, expanding the use of CPPs for 
selective tumour targeting [35][36]. The only cell-
penetrating peptide that has been tested in clinical trials 
is the so-called p28 peptide, which is derived from azurin 
protein and induces an increase of p53 and consequently 
cell death by apoptosis [37]. A completed phase I study 
(NCT00914914) and an ongoing phase I study 
(NCT01975116) have been carried out with the p28 
peptide used as an anticancer drug for different types of 
tumours [38]. As far as we know, this p28 peptide has 





Used name Biological Target Clinical trials status 
Remarks and references of 







domain of p53 
p28 alone in phase I (NCT01975116 
and NCT00914914) 








Phase I/II for cancer diagnostic by 
positron emission tomography 
(NCT01806675, NCT00565721, 
NCT01492192, NCT01961583) 
Montet et al. 2006 
Xie et al. 2008 
Nazli et al. 2012 
Chlorotoxin 
(CTX) 
Binding affinity  
for gliomas and 
neuroectodermal 
tumors 
Phase I for cancer imaging and 
safety study 








Phase I/IIa, Study to Assess Safety, 
Tolerability, Pharmacokinetics and 
Preliminary Efficacy on Advanced 
Solid Tumors (NCT01711398) 
Latorre et al. 2014 
(submitted) 
Destouches et al. 2011 
Antibodies Trastuzumab Her2/neu receptor 
Accepted by FDA and over the 
world (Herceptin as commercial 
formulation for breast cancer) 




factor (anti PDGF-B) 
Phase III for Age-
Related Macular Degeneration  
(in complement with other anti-
VEGF drug) NCT01940900 
No research studies  
with IONPs 
Folic Acid Folate Folate receptors 
Several clinical studies of folic acid 
conjugated to anti-cancer drugs 
(NCT00485563, NCT00485563, 
NCT00291785, etc.) 
Fan et al. 2011 
Table 2. Examples of biomolecules approved for clinical applications or already in clinical trials that are used in IONPs 
functionalization research studies 
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3.2 Antibodies and other proteins 
Antibodies are complex protein molecules that bind to 
specific antigens with high affinity. Antibodies can be 
developed to bind to almost any given antigen, for 
example, specific receptors expressed on the surface of 
cells, and are therefore very useful tools to target disease 
biomarkers. Apart from their use as anticancer agents [39], 
antibodies have been used in IONP functionalization for 
their targeting properties toward cancer cells for a decade. 
As shown in the preliminary and encouraging study of 
Kang et al. in 2002 [40], IONPs can be functionalized with 
an antibody against E-selectin, an adhesion molecule 
induced in cancer cells. The final nanostructure was able to 
bind HUVEC cells specifically when the overexpression of 
E-selectin is previously activated. 
 
Numerous research groups are interested in the 
functionalization of IONPs with trastuzumab, a 
commercial and approved antibody for breast cancer 
treatment [41], for the development of targeted 
therapeutic strategies. Most of the studies confirmed the 
selectivity of the antibody-functionalized IONPs toward 
cell lines overexpressing the Her2 receptor, depending on 
receptor expression level [42][43]. Vigor et al. showed 
similar results using another antibody that binds 
carcinoembryonic antigen (CEA), a receptor 
overexpressed in colorectal cancer cells [44]. The use of 
antibodies for intracellular uptake of IONPs is currently 
developing and several works have examined the cell line 
specifically targeting the enhancement of the uptake. 
 
Additionally, other proteins are being used to functionalize 
IONPs and improve the cellular uptake and cell targeting. 
The example of transferrin-functionalized IONPs to target 
cancer’s overexpression of transferring receptors has been 
recently published by Piraux et al. in 2013 [45]. 
 
3.3 Targeting peptides 
 
Apart from macromolecules such as antibodies and CPPs, 
smaller peptides also interact with specific receptors in 
the cell membrane and increase the cellular uptake of the 
functionalized IONPs.  
 
Arginine-glycine-aspartic acid, also known as RGD 
peptide, binds to the integrin receptor (αvβ3) which is 
overexpressed in several cancer cell lines and is 
commonly used as a targeting agent. Several works show 
that the functionalization of IONPs with RGD peptide (in 
linear or cyclic conformation) induces a significant 
increase in the cell uptake, compared to bare IONPs, 
specifically for αvβ3 positive cell lines as in some cancer 
cell lines (BT-20 and HeLa) and no significant changes in 
αvβ3 negative cells (9L, MCF-7, or U87MG cells) 
[46][47][48]. Similarly, chlorotoxin (CTX) is a 36-amino 
acid peptide that has a high selectivity and binding 
affinity for gliomas and neuroectodermal tumours [49]. 
Sun et al. showed a tenfold increase in the cellular uptake 
of CTX-functionalized IONPs compared to bare IONPs in 
9L cells [50]. Nucant pseudopeptide (N6L) is a 4-kDa 
pseudopeptide currently in phase II clinical trials 
(NCT01711398), while the MultiFun European project 
(EU-FP7 no. 262943) is currently working on the 
multifunctionalization of IONPs with N6L and anticancer 
drugs. The significance of this pseudopeptide is that it 
acts as a targeting agent through its specific binding to 
nucleolin and nucleophosmin (overexpressed in several 
cancers) and also as a therapeutic agent [51][52]. The first 
results obtained showed the targeted uptake of N6L 
covalently-functionalized IONPs and the controlled 
release of N6L in a reducing medium which mimics the 




Aptamers are single-stranded oligonucleotides that bind to 
their specific targets with high efficiency. Aptamers have 
been used for the targeting and specific cellular uptake of 
IONPs, as they present several advantages, such as their 
easy and reproducible synthesis, their good stability and 
their lack of immune response. Chen et al., in 2011, 
developed PEG-IONPs functionalized with doxorubicin 
and sg8c aptamer. Sg8c binds to the cell membrane 
receptor protein tyrosine kinase 7 (PTK7). The study 
showed a clear specificity of sg8c-functionalized IONPs for 
PTK7 positive cells compared to PTK7 negative cells in 
correlation with the cytotoxicity of released doxorubicin 
under high pH of lysosome medium, which also showed a 
receptor-mediated entrance [53]. 
 
3.5 Carbohydrates 
Functionalization of IONPs with carbohydrates can 
improve cellular uptake by two different strategies: (1) 
providing higher hydrophilicity and biocompatibility and 
thus increasing lifetime in the bloodstream; and (2) the 
interaction with specific sugar receptors on the 
membrane of certain cell lines, including cancer cells [54]. 
Moros et al. studied the uptake of IONPs functionalized 
with monosaccharides (glucose or galactose) compared to 
IONPs functionalized with PEG and showed that the type 
of carbohydrate affects the rate and the mechanism of 
internalization [55]. In 2011, Valero et al. also showed 
interesting results using IONPs encapsulated within 
apoferritin (apomaghemite) and then functionalized with 
two carbohydrates, N-acetyl-D-glucosamine and D-
mannose. First, they found similar behaviour to an MRI 
contrast agent such as the commercial agent Endorem. 
Finally, they also observed that both carbohydrate-
functionalized apomaghemite NPs retained the 
carbohydrate lectin recognition activity [56]. 
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Figure 3. Functionalization of IONPs. Schematic representation to scale of IONPs and the structure of different molecules used for their 
functionalization. Structures represented: IONPs, doxorubicin, RGD peptide (PDB ID: 3VI4), chlorotoxin (PDB ID: 1CHL), azurin p28 
peptide (PDB ID: 4AZU), Nucant (N6L) [52], aptamer (PDB ID: 4HQU) and antibody (PDB ID: 1IGT). 
 
 
Figure 4. A. Different internalization pathways of IONPs in mammalian cells. Possible mechanisms of uptake including 
macropinocytosis, caveolae- and clathrin-mediated endocytosis, phagocytosis, passive diffusion and other endocytosis pathways. After 
internalization, IONPs can produce cytotoxicity effects via a Fenton reaction. Hydroxyl radicals generated could damage DNA, proteins 
or lipids (8-OH-dG = 8 hydroxydeoxyguanosine, MDA = malondialdehyde, HNE = 4-hydroxy-2-nonenal), triggering genotoxicity. B. 
IONP administration in the human body, such as intrathecal, intratumoural, intravenous and intramuscular or subcutaneous methods. 
 
8 Nanobiomedicine, 2014, 1:2 | doi: 10.5772/58841
 
3.6 Folic acid 
Folic acid, also known as Vitamin B9, is a natural product 
with an important role in DNA and RNA synthesis. Over 20 
years, folate receptors have been shown to be overexpressed 
on several cancer cell lines and can therefore be used for 
targeting cancer cells and activated macrophages [57][58]. 
Folic acid has already been approved for several clinical 
applications. Clinical trials are in progress for drug-folate 
conjugate use in cancer diagnosis (NCT00003763) and 
therapy (NCT00291785, NCT00485563, NCT00441870). Folic 
acid has been widely used for 15 years in the development of 
NP targeting strategies for biomedical applications, 
including IONPs. We highlight the work of Fan et al. in 
2011, where a significant enhancement of cellular uptake of 
the folic acid-functionalized IONPs is achieved compared 
to bare IONPs, depending on the receptor expression levels 
of the cell lines used. Promising results of MRI in vivo 
highlight the potential of folic acid-functionalized IONPs 




The functionalization of IONPs with drugs for their 
application as nanocarriers is a wide and much studied topic 
[60]. Indeed, the major portion of the drugs used in 
combination with IONPs at the research level are already 
available in clinics, such as doxorubicin, gemcitabine and 
SN38, and are also involved in several clinical trials of drug-
targeting agent conjugates. Currently, there are some 
promising examples of doxorubicin conjugated with 
antibodies now in clinical trials (NCT00051584), and the use 
of liposomal formulations for drug delivery (NCT01227941).  
 
The multifunctionalization of IONPs by targeting agents 
and drugs, and its acceptance in clinical processes, might 
be a breakthrough in the development of specific therapies. 
The presence of targeting moieties such as those discussed 
above will increase the localization of IONPs in the 
diseased tissue, therefore augmenting drug delivery and 
local drug concentration. Thus, research is currently 
making efforts towards the multifunctionalization of 
IONPs. Different methodologies need to be developed to 
ensure controlled multifunctionalization, and preserve 
the stability and biological activities of active molecules 
attached to the particles. Additionally, with respect to the 
clinical application of these nanostructures, 
functionalization efforts are required to increase the blood 
half-life of the IONPs, minimizing off-target accumulation 
and immunological response.  
 
4. Toxicological profiles and potential interference with 
biological functions of cells 
 
The above-mentioned parameters have a tremendous 
influence on cell internalization as well as in vivo 
behaviour, and hence in the administration procedure of 
choice for clinical applications [61]. Mammalian cells 
internalize IONPs mainly through endocytosis 
mechanisms. However, the specific pathway depends on 
the cell type and physicochemical features of the IONPs. 
Most cells use different molecular pathways of pinocytosis, 
whereas cells from the reticuloendothelial system (RES) 
preferentially internalize IONPs by phagocytosis in a 
process that begins with the opsonization of the NPs in the 
bloodstream, followed by binding of the opsonized NPs to 
the cell surface and final ingestion [62] (Figure 4A). The 
IONPs approved for clinical use are not functionalized, but 
they display a variety of sizes that influence their 
administration and distribution within the body. SPIONs 
and USPION accumulate in the lungs, liver, spleen, lymph 
nodes, bone marrow vessels and capillaries, while 
VSPIONs also accumulate in the kidneys (Figure 4B). Once 
in the body, the iron of the NP core is stored in the red 
blood cells and, like the endogenous iron, it is 
progressively eliminated via faeces, while the coating 
(mostly dextran-derived compounds) degrades and is 
eliminated by the kidneys. However, the IONPs interact 
with different biological systems in the body and may have 
adverse effects. Evaluating the toxicological effects of 
IONPs both in vitro and in vivo is crucial for the 
development of IONP-derived applications in medicine. 
 
4.1 Effects on cellular physiology 
4.1.1 Mitochondrial stress 
One factor that can contribute to nanotoxicity is the size of 
the NPs. Smaller NPs have a greater reactive surface area 
than larger ones, are more chemically reactive, and 
produce greater numbers of reactive oxygen species (ROS) 
that include free radicals [63]. SPIONs also can induce 
(geno-)toxicity via generation of ROS. SPIONs are 
presumably degraded into iron ions within the lysosomes 
by hydrolysing enzymes effective at low pH [64]. This 
“free iron” can potentially cross the nuclear or 
mitochondrial membrane and, in the latter case, the free 
iron in the form of ferrous ions (Fe2+) can react with 
hydrogen peroxide and oxygen produced by the 
mitochondria to produce highly reactive hydroxyl radicals 
and ferric ions (Fe3+) via the Fenton reaction (Figure 3.a). 
Therefore, hydroxyl radicals generated by the free iron 
could damage DNA, proteins, polysaccharides and lipids 
in vivo [65]. The cytotoxicity was also found to be 
dependent on various factors, such as type of surface-
coating or its breakdown products, chemical composition 
of cell medium, oxidation state of iron in SPION and 
protein–SPION interaction [24][66][67]. For example in 
IONPs, magnetite (Fe3O4) and maghaemite (Fe2O3) can 
show different cellular responses because of their ability to 
undergo oxidation/reduction reactions. In fact, magnetite 
has been shown to cause higher levels of oxidative DNA 
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lesions in the A549 human lung epithelial cell line in the 
absence of decreased cell viability as compared to 
maghaemite, owing to its potential to undergo oxidation. It 
is hypothesized that the toxicity can, however, be 
decreased by coating magnetite NPs, resulting in fewer 
oxidative sites that are less reactive, thereby producing less 
DNA damage [66]. 
 
4.1.2 Effects on actin cytoskeleton architecture 
 
Intracellular accumulation of NPs can have profound 
effects on cell morphology. High levels of internalized 
particles can provoke cellular stress, inducing changes in 
the architecture of the actin cytoskeleton. An altered actin 
network displaying actin stress fibres can lead to a reduced 
proliferative capacity and cell spreading. It can also 
influence the migration and differentiation of stem cells. 
 
In the case of IONPs, it has been reported to interfere with 
actin and tubulin structures, inducing cell retraction, 
rounding and deposition of massive dense filament matters 
adjacent to the nucleus and vacuoles in the cytoplasm [68]. 
 
4.2 Factors that can contribute to non-toxicity 
 
Size is clearly a key factor in determining the potential 
toxicity of a particle. However, it is not the only important 
factor. Other properties of nanomaterials that influence 
toxicity include chemical composition, shape, surface 
structure, surface charge, aggregation and solubility [63]. A 
study investigating the effect of different surface coatings on 
cell behaviour and morphology has shown that dextran-
magnetite (Fe3O4) NPs result in cell death and reduced 
proliferation similar to that caused by uncoated IONPs [24]. 
Other authors have reported the formation of gas vesicles 
after exposure to the uncoated NPs, resulting in altered 
protein functions and changes in ionic equilibrium within 
the cells, which also promotes toxicity [69]. 
 
4.3 In vitro and in vivo toxicity of nanoparticles  
in 2D vs. 3D cell culture 
 
Common 2D cell cultures do not adequately represent the 
functions of 3D tissues that have extensive cell–cell and 
cell–matrix interactions, as well as markedly different 
diffusion/transport conditions. Hence, testing cytotoxicity 
in 2D cultures may not accurately reflect the actual toxicity 
of NPs and other nanostructures in the body [70]. For 
instance, recent studies on toxicity testing of magnetic NPs, 
using in vitro 2D cell culture, demonstrated high cytotoxic 
effects. However, when they were tested in animal models, 
no adverse effects were observed [71]. Therefore, in vitro 
3D cell culture models have been introduced to bridge the 
gap between in vitro 2D cell culture and in vivo models. 
Some authors report that bare IONPs were more toxic at 
lower concentrations in 3D culture, compared with 2D 
culture cells. This may be due to the increased contact area 
between NPs and cells in 3D culture [72]. 
 
When IONPs enter the body, absorption can occur through 
interaction with biological components such as proteins 
and cells; afterwards, they can distribute into various 
organs where they may remain in the same nanostructure 
or become metabolized [73]. A systematic and thorough 
quantitative analysis of the pharmacokinetics (i.e., 
absorption, distribution, metabolism and excretion) of 
IONPs can lead to improvements in design of 
biocompatible IONPs, a better understanding of NPs’ non-
specificity toward tissues and cell types, and assessments 
of basic distribution and clearance that serve as the basis to 
understand their activity and potential toxicity [74]. 
 
The surface of IONPs is rapidly covered by selective sets 
of blood plasma proteins after injection. Small IONPs (< 
10 nm) are usually rapidly removed through 
extravasation and renal clearance, whereas large IONPs 
(> 200 nm) are sequestered by the spleen via mechanical 
filtration [75]. The typical final biodistribution of IONPs 
is 80–90% in liver, 5–8% in spleen and 1–2% in bone 
marrow, due to the high number of macrophages 
contained in these organs [61]. IONPs were also found to 
be distributed in the brain, liver, spleen and lungs after 
their inhalation, demonstrating their ability to cross the 
blood–brain barrier [76] (Figure 4A).  
 
5. Current clinical applications  
 
In December 1996, the United States Food and Drug 
Administration (FDA) approved GastroMARK (AMAG 
Pharmaceuticals), an aqueous suspension of silicone-
coated, superparamagnetic iron oxide NPs, intended for 
oral administration, as a magnetic resonance (MR) 
imaging contrast medium to enhance the delineation of 
the bowel to distinguish it from organs and tissues that 
are adjacent to it in the upper regions of the 
gastrointestinal tract (www.fda.gov). The approval of 
GastroMARK, together with a number of preclinical 
studies supporting the potential use of SPIONs in 
different medical applications, contributed significantly 
to expanding clinical research in nanomedicine. A 
number of new SPION-derived products were 
developed, some of which were also approved by the 
FDA and the European Commission (EC) for clinical use. 
Additionally, the increasing number of clinical trials 
using these new NPs expanded their potential medical 
applications. Sixteen years later, just two SPION-derived 
products are approved by the FDA and commercially 
available: GastroMARK and ferumoxytol (Table 3). In the 
following paragraphs, we will describe the current 
clinical applications of SPION-derived products, as well 
as the clinical trials testing them for promising 
applications such as cell tracking and hyperthermia. 
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Date Events Indication Size Adm.
1996 Lumirem (Gastromark (US)):  approved by 
FDA 
Contrast agent for MRI for the 
gastrointestinal tract 
50 nm Oral 
1996 
Ferumoxides (Emdorem (EU) or Feridex 
1.V.): approved by the FDA 






Ferucarbotran (Resovist or (Cliavist(EU)): 
approved for Europena Market 






Ferumoxtram (Sinerem (EU) or (Combidex 
(US)): AMAG Pharma received an 
approvable letter from the FDA 
Detection and characterization of 
metastatic lymph nodes in 





Sinerem: submitted European Marketing 
Authorization Application  
Detection and characterization of 
metastatic lymph nodes in 





Feraheme (Ferumoxytol): approbed  
by the FDA 
Iron replacement therapy for the 
treatment of iron deficiency 
anemia in adult patients with 
chronic kidney disease.  
20-50 nm intravenous 
2012 Feraheme (Ferumoxytol): approbed  
by the EC 
Iron replacement therapy for the 
treatment of iron deficiency 
anemia in adult patients with 
chronic kidney disease.  
20-50 nm intravenous 
Table 3. Iron oxide nanoparticles (ION) for clinical applications: the table displays the chronology of ION approved by the Food and 
Drug Administration (FDA) and/or the European Commission (EC), discontinued and/or production abandoned. Sinerem’s 
Authorization Application was withdrawn by Guerbet (European partner of AMAG Pharma) in 2007. Ferumoxide was discontinued by 




Clinic imaging technologies rely on the use in MRI, optical 
imaging/MRI and MRI/PEP. SPIONs function as a negative 
contrast agent, decreasing T2 signals and thus the signal 
intensity. They cause a magnetic field gradient that affects 
the surrounding protons of water molecules, disrupting 
the homogeneity of the magnetic field, which can be 
observed by MRI [77]. Additionally, SPIONs display 
lymphotropic properties, as phagocytes of the RES 
internalize them, causing local changes in magnetic 
properties. These features make the SPIONs an excellent 
alternative to complement current contrast agents in MRI, 
providing higher accuracy in some conditions such as 
autoimmune diseases, cardiovascular and cerebrovascular 
pathologies, and cancer (Table 4). Additionally, the low 
toxicity both in vitro and in vivo, and their feasibility in 
enhancing the contrast of cellular targets in MRI, make 
then suitable for in vivo tracking of transplanted cells 
(Figure 5) [78]. 
 
5.1.1 Diagnostic tools 
5.1.1.1 Diagnosis in immunological diseases  
Autoimmune disease and inflammation processes are 
characterized by the activation of the endothelium that 
eventually allows for the extravasation of macrophages 
from the bloodstream into the inflamed tissue. SPIONs 
significantly enhance the signal of these events when 
analysed by MRI, as they are quickly captured by 
macrophages. In the last few years, a number of authors 
have taken advantage of this observation and carried out 
different clinical assays to test the value of SPIONs as a 
negative contrast in a variety of autoimmune and 
inflammatory conditions. Oral USPION (ferumoxytol) 
improved the detection of Crohn’s disease [79] and the 
prognosis of active ulcerative colitis [80][81]. Using 
ferumoxtran, a significant improvement was observed in 
a small cohort of Type 1A diabetes patients 
(NCT00585936) in the diagnosis of pancreatic islet 
inflammation when compared to T1-gadolinium [82]. In 
patients with multiple sclerosis, USPION-based MRI 
showed that iron oxide NPs labelled larger and better 
defined areas, allowing the detection of what has been 
referred to as normal-appearing white matter that is 
histologically affected (NCT01973517) [83][84]. These 
outstanding results have encouraged physicians and 
researchers to continue testing the SPION-based MRI in 
both the previous and new immunological and 
inflammatory conditions. At least two more clinical trials 
were running at the time of writing this review (Table 4). 
 
5.1.1.2 Diagnosis in cardiovascular  
and cerebrovascular pathologies 
The use of SPIONs for T2 and T2-weighted 
cardiovascular magnetic resonance imaging (CMR) has 
been successfully validated to detect myocardial oedema 
and myocardial haemorrhage [85][86]. In a more recent 
trial, Vilmaz et al. demonstrated that ferumoxytol 
significantly improved the signal in the myocardial 
infarction area when compared with gadolinium-based 
contrast images. This improvement was due to the 
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accumulation of USPIONs in infiltrating macrophages 
[87]. Similarly, Sigovan et al. demonstrated that 
ferumoxytol-enhanced MR angiography rendered 
superior image quality compared with non-enhanced 
time-of-flight MR when studying upper extremity 
autogenous fistulas in patients with renal failure. The use 
of ferumoxytol reduced flow artefacts while 
simultaneously raising lumen depiction scores, thus 
obtaining a more homogeneous luminal signal 
enhancement [88]. The ability to detect macrophage 
activity of plaque inflammation by MRI has also 
supported the use of SPION-based MRI of carotid 
atherosclerosis to predict cerebrovascular and 
cardiovascular morbidity and mortality. The author 
found an interesting association between USPIO-defined 
plaque inflammation and the development of vascular 
events, although the association was not significant due, 
in part, to the relatively low baseline risk of vascular 
event of the patient included in the clinical trial [89]. 
However, the overall data available from different trials 
aim to leverage the SPION-based MRI to assess the 
diagnosis of cardiovascular and cerebrovascular 
pathology in the next year. Thus it will be very important 
to pay special attention to the results derived from the 























































































Table 4. ClinicalTrials.gov search with the number of results and reference ID. Search terms: Superparamagnetic OR Iron Oxide OR 




Figure 5. Organ distribution of systemically injected nanoparticles. a. Common organ distribution is shown as a function of particle size. 
b. Example of the 99mTc-labeled graft copolymer used in a human patient and 89Zr-labeled cross-linked dextran nanoparticles used in a 
mouse model. This figure was reproduced with permission from Nature Materials [126]. 
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5.1.1.3 Diagnosis in cancer 
 
In healthy liver, spleen and lymph node tissue, IONPs 
decrease the MR signal intensity as phagocytic cells 
uptake the nanoparticles, while malignant tissue 
generally fails to uptake IONPs and appears bright 
relative to the surrounding tissue [90][91]. This 
observation emphasizes the IONP-enhanced MRI as an 
extremely promising imaging technique for the pre-
operative detection of metastatic disease in lymph nodes. 
In 2003, Harisinghani et al. reported that high-resolution 
MRI with IONPs (Sinerem) allowed the detection of small 
and otherwise undetectable lymph-node metastases in 
patients with prostate cancer, demonstrating the 
sensitivity and specificity of the technique [92]. From this 
point of departure, a number of clinical trials have 
successfully tested the IONP-enhanced MRI to detect 
sentinel lymph nodes in prostate cancer [93][94], as well 
as other types of cancers like bladder [95], breast 
(Endorem [96] and Resovist [97][98]) and renal cell 
(Sinerem) [99], among others (Table 4).  
 
5.1.2 Cell tracking in cell transplantation-mediated therapies 
 
Cell therapy relies on the delivery of cells to the target 
site. Monitoring and tracking these cells to ensure tissue 
delivery and engraftment become a key issue in 
stabilizing clinical safety and therapeutic efficacy. In this 
sense, detection by MRI of IONP-labelled cells may be 
one of the most promising approaches for a short-term 
evaluation [100]. Although the FDA and EC have not yet 
approved their use for in vivo cell tracking, a few clinical 
trials have evaluated their feasibility and safety in 
different contexts (NCT00972946, NCT01169935 and 
NCT01127113). To evaluate the feasibility, safety and 
immunological effects of intrathecal and intravenous 
administration of autologous mesenchymal stem cells in 
patients with multiple sclerosis (MS) and amyotrophic 
lateral sclerosis, Karussis et al. designed and carried out a 
clinical trial in which MSC were magnetically labelled 
with ferumoxides. The MSC were incubated with 
ferumoxides in the presence of poly-L-lysine for 24 to 48 
hours prior to transplantation. MRI examination of the 
brain and spinal cord was performed at 24 and 48 hours, 
and later at one to three months. The image revealed a 
possible migration of such cells to the meninges of the 
spinal cord and nerve roots, and to the spinal cord 
parenchyma, although they could not rule out the 
possibility that macrophages had phagocytized the iron 
oxide magnetic NPs and migrated to the inflammatory 
MS lesions [101]. In a different work, Richards et al. 
successfully SPION-labelled human peripheral blood 
mononuclear cells (PBMC) and performed intramuscular 
and intravenous administration of labelled cells in 
healthy volunteers without remarkable side effects. After 
administration of labelled cells, the signal intensity was 
reduced in the liver and spleen, reflecting dose-
dependent accumulation of SPION-labelled cells. This 
work demonstrated that labelled cells can be visualized in 
vivo at clinically relevant field strengths after local or 
systemic administration, and that SPION-labelled cells 
can be tracked to a site of focal inflammation in humans. 
More importantly, however, they demonstrated that 
intravenous administration of SPION-labelled cells in 
humans is safe [78].  
 
Cancer immunotherapy approaches can also benefit from 
SPION labelling technology. Dendritic cell (DC) vaccines 
have been used to induce tumour-specific cytotoxic T 
cells. To be successful, injected DCs need to migrate to 
the lymph nodes (LNs) where they can stimulate effector 
T cells. DCs have previously been labelled with 
radionuclides for scintigraphic imaging, which is the only 
clinical cellular imaging modality approved by the FDA 
[102][103]. deVris et al. investigated the biodistribution of 
SPION-labelled DCs applied as cancer vaccines in 
melanoma patients using MRI, and demonstrated that 
MRI allowed assessment of the accuracy of DC delivery 




Iron oxide NPs have been successfully used as a carrier 
for bioactive molecules in a number of conditions both in
vitro and in animal models [105]. In the last few years, 
SPIONs have also been demonstrated to be useful in 
clinical settings (NCT01270139, NCT01436123 and 
NCT01927887). In 2009 Provenzano et al. reported that 
rapid intravenous injection of ferumoxytol led to 
significantly greater haemoglobin increases compared 
with oral iron, and was also well tolerated in all patients 
[106]. The same year, ferumoxytol was approved by the 
FDA, and later in 2012 by the EC, as an iron replacement 
therapy indicated for the treatment of iron deficiency 
anaemia in adult patients with chronic kidney disease. 
Since then, a number of clinical trials have extended the 
use of ferumoxytol as intravenous iron delivery/therapy 
to other iron deficiency conditions. Ferumoxytol was 
effective and well tolerated in adult patients with iron 
deficiency anaemia in whom oral iron was ineffective or 
could not be used [107][108], and showed comparable 
efficacy and adverse event rates to the first choice, iron 




Thermotherapy of solid tumours is one of the most 
promising applications of SPIONs, either alone or in 
combination with adjuvant treatments, such as 
chemotherapy or radiation. The principle of applying 
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IONPs to hyperthermia therapy involves the 
administration of an IONPs fluid within the tumour, 
followed by the application of an alternating magnetic 
field. These nanoparticles achieve high temperatures, 
promoting warming of the region. Temperature elevation 
in the range of 41-46 ºC can induce several effects at both 
cellular and tissue levels [111]. Cellular hyperthermia 
induces heat stress, resulting in high level of heat-shock 
protein expression, protein denaturation and folding and 
apoptosis. At the tissue level, temperature elevation 
induces changes in pH, perfusion and oxygenation of the 
tumour microenvironment [112][113], while higher 
temperature (hyperthermia) or longer treatment time 
may lead to necrosis.  
 
Clinical studies for the application of thermotherapy 
using IONPs in humans were initiated in 2007 on prostate 
cancer and glioblastoma patients (NCT02033447 and 
DRKS00005476). Johannsen et al. injected the IONPs fluid 
transperineally into the prostate of ten patients who 
received six thermal therapies of 60 minutes duration at 
weekly intervals. They reached maximum temperatures 
of 55 ºC in the prostate with a median temperature of 40.7 
ºC within the tumour and 40.2 ºC in peritumoural zones. 
With this assay they demonstrated the feasibility of 
thermotherapy [114]. Afterwards, they carried out a 
different clinical assay demonstrating that interstitial 
heating using IONPs was feasible and well tolerated in 
patients with locally recurrent prostate cancer, and the 
deposition of nanoparticles in the prostate was highly 
durable [52]. 
 
In parallel, Maier-Hauff et al. evaluated the feasibility and 
tolerability of thermotherapy in patients with recurrent 
glioblastoma multiforme. In this trial, patients received 
four to 10 thermotherapy treatments, reaching a median 
intratumoural temperature of 44.6 ºC. The authors 
observed that thermotherapy using IONPs was tolerated 
well by all patients with minor or no side effects [115]. A 
few years later, they carried out another clinical trial and 
observed that the median overall survival following 
diagnosis of first tumour recurrence was 13.4 months, 
which was an improvement compared to the 6.2 months 
in other reference studies in the field. Additionally, the 
median of overall survival after primary tumour 
diagnosis was 23.2 months, compared with just 14.6 in 
the reference groups [116]. 
 
More recently, Matsumine et al. reported the utilization of 
hyperthermia in patients with metastatic bone tumours. 
The authors carried out an initial surgical intervention 
followed by the implantation of a mixture of “bare” 
magnetite NPs and calcium phosphate cement, which is a 
biocompatible bone substitute. The patients were treated 
for 15 minutes every two days starting from the eighth 
day after surgery. Thirty-two percent of lesions were 
reduced and presented visible bone formation, 64% 
showed no progressive lesions for more than three 
months and just 4% presented a poor response to the 
treatment, demonstrating safety and effectiveness [117]. 
 
Although these results are promising, the development of 
therapies based on magnetic hyperthermia is still in its 
very early stages. In the next few years, many biological 
and technical advances need to be achieved before this 
new therapy becomes part of the standard of care for 
some cancers. Questions such as how to reach 
homogenous distribution of IONPs and therapeutic 
temperature, and how to minimize peritumoural tissue 
damage, need to be addressed. In this regard, a new 
phase 0 clinical trial to investigate the magnetic 
nanoparticle thermo-ablation-retention and maintenance 
in the prostate is being performed by the University 
College London Hospitals (NCT 02033447). In this trial, 
the authors will test whether the magnetic nanoparticles 
actually stay where they are injected or move to sensitive 
structures around the prostate, which may lead to 
undesirable side effects. Finally, MagForce is conducting 
a new open-label, randomized clinical trial employing 
magnetic hyperthermia to treat glioblastoma multiforme 
patients (DRKS00005476). The purpose of this trial, 
expected to enrol up to 285 patients, is to test the 
feasibility and safety of using magnetic hyperthermia as a 
stand-alone therapy and in combination with 
radiotherapy using the commercial IONPs NanoTherm®. 
The results will help magnetic hyperthermia advance in 




Bare IONPs are currently employed in an increasing 
number of clinical trials. In the next decade, we will see 
them settle into clinical practice for imaging-based 
diagnosis for a wide range of diseases. One of the main 
entries of IONPs into the scene of medical application 
will surely come from their functionalization possibilities. 
These will provide them with the capacity to target 
specific cells within the body, and hence develop specific 
therapies and diagnostic tools. The main advantages of 
using nanocarriers for specific drug delivery are the 
reduction of side effects, potential drug resistance and 
increased drug payload. As unique targeted nanocarriers 
can deliver hundreds of small drug molecules, clinical 
practices shall be adapted to incorporate these new 
strategies. They should include treatment protocols 
personalized by choosing appropriate formulations with 
defined targeting moieties and drug loads. The 
multifunctionalization of IONPs opens the door to 
multimodal therapeutic approaches by combining the 
dual effects of magnetic hyperthermia and chemotherapy, 
using multiple drugs in the same IONP formulation. 
Additionally, functionalization of IONPs will allow 
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researchers to tune and optimize IONPs’ 
biocompatibility, blood half-life and immunogenicity, key 
parameters required to successfully bring these 
innovative nanotechnology-based tools from research 
laboratories to clinics. Overall, the multifunctionalization 
of IONPs is a critical step. It is most likely that it will be 
broadly implemented in the near future for new 
nanoformulations for both diagnosis and therapy. 
 
In the particular case of IONPs for magnetic 
hyperthermia, a number of fundamental and practical 
aspects still require more research. One of these concerns 
the magnetic and mechanical behaviour of IONPs inside 
cells: specifically, we refer to lysosomes under dynamic 
external fields. Although a few theoretical studies 
addressing this matter have appeared [118], we require 
specific experimental approaches to confirm their 
predictions. Additionally, more work needs to be done to 
determine the actual heating mechanisms under common 
frequency and field amplitude conditions, and to 
evaluate the involvement of any other physical 
phenomena. In this sense, the results from a very recent 
publication exploring possible damage to the lysosomal 
membrane by a remotely induced torque over IONPs are 
particularly encouraging [119]. The role of phonon-
mediated heating and its coupling to those biomolecules 
in the surroundings, or directly linked to IONPs, is now 
receiving more attention [120]. These studies will enable 
us to discern whether or not a sizeable macroscopic 
temperature change is required to have a therapeutic 
effect. If not, temperature changes on the micro- or nano-
scale could be enough to induce cell death or, at least, to 
sensitize cancer cells to other treatments 
(chemo/radiotherapy). Finally, the possibility of having 
magnetic hyperthermia in an MRI machine has been 
proposed [121-122], but no clear steps have been taken to 
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